LIVALO pitavastatin 4 mg film-coated tablet blister pack

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

pitavastatin calcium, Quantity: 4.18 mg (Equivalent: pitavastatin, Qty 4 mg)

Disponibbli minn:

Advantage Medical Products Consulting Pty Ltd

INN (Isem Internazzjonali):

pitavastatin calcium

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: aluminium magnesium silicate; lactose monohydrate; hypromellose; triethyl citrate; magnesium stearate; hyprolose; titanium dioxide; colloidal anhydrous silica

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

100, 10, 30, 28

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

Livalo is indicated as an adjunct to diet for the treatment of adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, when response to diet and other non-pharmacological measures is inadequate. Prior to initiating therapy with Livalo, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Sommarju tal-prodott:

Visual Identification: Round biconvex white film-coated tablets embossed on one side with 'KC' and '4' on the other side; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2013-08-27